Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05374928 · ClinicalTrials.gov registry record
Human Epilepsy Project 3
A clinical trial of Idiopathic Generalized Epilepsy, sponsored by NYU Langone Health.
- Active
- Registry status
- 320
- Enrollment target
- 18
- Study locations
NCT05374928 is a study of Idiopathic Generalized Epilepsy that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 320 participants. The trial reports 18 study locations across 14 states.
The verdict
NCT05374928, a study of Idiopathic Generalized Epilepsy, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 18
- Study locations
Study Summary
By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to make more informed decisions about the factors affecting their quality of life, including plans for driving, relationships, pregnancy, schooling, work, and play. In addition to its impact on clinical care, the data and specimens collected in HEP3, including sequential electrophysiology, biochemical profiles and neuroimaging and banked DNA for future genomics studies, have the potential to provide new insights into the biological basis of IGE, thereby advancing the discovery of effective treatments and cures. By enrolling both newly diagnosed subjects (prognosis unknown) as well as subjects with established IGE who are already determined to be treatment resistant or treatment responsive, the study team can immediately test potential biomarkers in a confirmation cohort, which will accelerate identification of predictive biomarkers.
Conditions Studied
Study Locations (18)
New York
- NYU Langone Health - Comprehensive Epilepsy Center (CEC) - New York
- Mount Sinai Hospital - New York
- Northwell Health - New York
Maryland
- The Johns Hopkins Hospital - Baltimore
- Mid-Atlantic Epilepsy Sleep Center - Bethesda
Minnesota
- Mayo Clinic - Rochester
- Minnesota Epilepsy Group - Saint Paul
California
- University of California San Francisco (UCSF) - San Francisco
Connecticut
- Yale University - New Haven
District of Columbia
- Georgetown University - Washington D.C.
Florida
- University of Miami - Miami
Maine
- Maine Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05374928
The ClinicalTrials.gov registry entry for NCT05374928 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Generalized Epilepsy appearing as the primary indexed condition, and to 0 interventions.
NCT05374928 reports 18 study locations spanning 14 distinct geographic areas - top geographies include New York, Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05374928 about?
NCT05374928 is a clinical study titled "Human Epilepsy Project 3". By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, inc...
What is the current status of trial NCT05374928?
This trial is currently active not recruiting. The enrollment target is 320 participants. The study started on 2020-03-09. Estimated completion is 2025-12.
What conditions does trial NCT05374928 study?
This clinical trial studies the following conditions: Idiopathic Generalized Epilepsy.
Who is sponsoring clinical trial NCT05374928?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05374928 being conducted?
This trial has 18 study locations across California, Connecticut, District of Columbia, Florida, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Generalized Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.